



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		MEMBER'S FIRST NAME:		
Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.				
			☐ URGENT	
MEMBER INFORMATION				
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
PATIENT INSURANCE ID NU	JMBER:			
MALE FEMALE HEIGHT (IN/CM): WEIGHT (LB/KG): ALLERGIES: IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: HTTPS://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI DISCLOSURE AUTHORIZATION.PDF				
PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:				
PRESCRIBER INFORMATIO	N			
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:		
			_	
MEDICATION OR MEDICAL	L DISPENSING INFORMATION			
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
DURATION OF THERAPY (SF	RENEWAL PECIFIC DATES):	IF RENEWAL: DATE THERAP	Y INITIATED:	
1-				

Continued on next page







Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST	MEMBER'S FIRST NAME:	
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO	
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:	
2. LIST DIAGNOSES:		ICD-10:	
 □ Type II diabetes □ Type II diabetes with established cardio □ Congestive heart failure □ Chronic kidney disease □ Other DiagnosisICD-10 			
	: PLEASE PROVIDE ALL RELEVANT CLIN	CAL INFORMATION TO SUPPORT A	
PRIOR AUTHORIZATION.			
Please provide documentation. Is the patient's most recent (pre-Jard	filtration rate (eGFR) below 20 mL/min	months or prior to starting	
Is the patient on dialysis? Yes N	r? 🗆 Yes 🗆 No <i>Please provide docume</i> lo	mucion.	
Is the patient currently on metformin	? □Yes □No		
Did the patient have an inadequate r *Please provide documentation	esponse or intolerance to metform?	⊒Yes □ No	
□ Estimated glomerular filtration rate	he following contraindications to metformed (eGFR) less than or equal to 20 mL/m sis, portal hypertension, ascites, and/o	in/1.73 m2	
	bin A1c level within the past 6months lusive? Yes No Please provide docu	· -	
Does the patient's body mass index(l	BMI) exceed 45kg/m²? ☐ Yes ☐ No		
Is the patient's estimated glomerular Please provide documentation.	filtration rate (eGFR) 20 mL/min/1.73 r	m2 or above? □ Yes □ No	
Is the patient's medical history positi Please check at least one of the follo ☐ MI or Stroke	ve for at least one of the following? wing:	Yes □ No	

© 2017–2023 by Magellan Rx Management, LLC. All Rights Reserved. Revision Date: 4/15/24 CAT0122







Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: ____

□ Imaging shows single-vessel or multi-vessel coronary artery disease
□ Previous coronary revascularization procedure
□ Positive cardiac stress test
□ Hospital admission for unstable angina
□ Occulsive peripheral arterial disease (defined as limb revascularization procedure, limb or foot amputation due
to circulatory insufficiency, imaging or non-invasive study showing evidence of more than 50% stenosis in an
artery, and/or ankle: brachial index equaling less than 0.9 in an ankle.)
For diagnosis of congestive heart failure, please answer the following:
Does patient have an ejection fraction(EF) equaling 40% or less? ☐ Yes ☐ No Please provide documentation.
Does patient have an ejection fraction(EF) greater than 40%? Please provide documentation.
Has patient ever had NYHA class II, III or IV symptoms of heart failure? ☐ Yes ☐ No Please provide documentation.
Does patient's body mass index(BMI) equal less than 45kg/m²? ☐ Yes ☐ No Please provide documentation.
Does patient have a NT-proBNP greater than 300pg/ml? □ Yes □ No Please provide documentation.
For patients with A-fib, is the NT-proBNP greater than 900pg/ml? Yes No Please provide documentation.
IF NT-proBNP not available, does patient have a BNP >100pg/ml without kidney failure? Yes No Please submit chart documentation.
If NT-proBNP not available and patient has kidney failure, does patient have a BNP>200pg/ml? Yes No Please submit chart documentation.
If NT-proBNP not available and patient has Atrial fibrillation (AF), does patient have a BNP>150pg/ml? \Box Yes \Box No Please submit chart documentation
Does the patient have structural heart disease such as one or more of the following:? ☐ Yes ☐ No <i>Please provide documentation from echocardiogram.</i>
□ LA width >4.0cm
□ LA length >5.0 cm
□ LA area >20cm2
□ LA volume >55ml
□ LA volume index >34ml/m2
Does the patient has left ventricular hypertrophy defined by at least one of the following:? No Please provide documentation from echocardiogram.
□ Septal thickness or posterior wall thickness >1.1 cm
□ LV mass index(LVMI) >115g/m2 for males and >95 g/m2 for females
□ E/e' (mean septal and lateral) >13
□ e´ (mean septal and lateral) <9cm/s
Has patient been hospitalized in the past 12 months before starting Jardiance(empagliflozin)? ☐ Yes ☐ No <i>Please</i> provide documentation.

© 2017–2023 by Magellan Rx Management, LLC. All Rights Reserved. Revision Date: 4/15/24 CAT0122









Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: MEMBER'S FIRST NAME:
s patient on a stable dose of a diuretic? Yes No Please provide documentation.
Has patient had a myocardial infarction, coronary bypass graft surgery or other major cardiovascular surgery, troke or TIA in the past 90 days of starting Jardiance? Yes □ No Please provide documentation.
las patient had a heart translplant? □ Yes □ No
Does patient have acute decompensated heart failure? □ Yes □ No
Does patient have severe <u>pulmonary disease</u> including severe COPD, requiring home oxygen therapy for their COPD, chronic nebulizer therapy or chronic oral steroid therapy for treatment of their severe COPD? Yes No Please submit chart documentation.
Does patient have severe <u>pulmonary disease</u> including primary pulmonary hypertension? — Yes — No <i>Please</i> submit chart documentation.
Does patient have any other condition or diagnosis causing patient's heart failure symptoms such as patient has significant mitral valve regurgitation causing the heart failure, any dilated cardiomyopathy, infiltrative cardiomyopathy, drug induced cardiomyopathy, or viral myocarditis? — Yes — No Please submit chart documentation.
Does patient have and eGFR less than 20ml/min/1.73m ² ? □ Yes □ No
Ooes patient require dialysis? □ Yes □ No
s patient's heart failure related to any of the following? Yes No Please check at least one of the following: infiltrative disease
accumulation disease
muscular dystrophy
hypertrophic obstructive cardiomyopathy
known pericardial restriction
□ valvular disease expected to lead to surgery □ atrial fib/flutter with a resting heart rate greater than 110 bpm
f prescribing for the diagnosis of chronic kidney disease(CKD), please answer the following:
las the patient had an estimated glomerular filtration rate(eGFR) ≥20 to <45 mL/min/1.73m² for 3 or more months? □ Yes □ No <i>Please submit chart documentation</i> .
Has the patient had an estimated glomerular filtration rate(eGFR) an eGFR ≥45 to <90 mL/min/1.73m² for 3 or more months? □ Yes □ No <i>Please submit chart documentation</i> .
Has the patient had a urinary albumin:creatinine ratio ≥200 mg/g (or protein:creatinine ratio ≥300 mg/g) for 3 or months? □ Yes □ No <i>Please submit chart documentation</i> . s patient taking either a renin-angiotensin-converting enzyme inhibitor(ACEi) or or an angiotensin II receptor blocker(ARB)? □ Yes □ No <i>Please submit chart documentation</i> .

© 2017–2023 by Magellan Rx Management, LLC. All Rights Reserved. Revision Date: 4/15/24 CAT0122







Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: MEMBER'S FIRST NAME:				
Is an ACEi or ARB contraindicated? Yes No Please submit chart documentation.				
Does patient have TypeII diabetes AND prior atherosclerotic cardiovascular disease with an cGFR >60ml/min/1.73m ² ? Yes No Please submit chart documentation.				
Is patient receiving both an ACEi and an ARB at the same time? ☐ Yes ☐ No				
Is patient receiving maintenance dialysis? □ Yes □ No				
Has the patient received a kidney transplant? □ Yes □ No				
Does patient have polycystic kidney disease? Yes No				
Does patient have Type1 diabetes? □ Yes □ No				
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?				
Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.				
ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.				
Prescriber Signature or Electronic I.D. Verification: Date:				
CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in re liance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.				

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program

Attn: CP - 4201 P.O. Box 64811 St. Paul, MN 55164-0811

